Innovax-ILT

RSS

avian infectious laryngotracheitis and Marek’s disease vaccine (live)

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Innovax-ILT. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Innovax-ILT.

For practical information about using Innovax-ILT, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.

This EPAR was last updated on 09/12/2021

Authorisation details

Product details
Name
Innovax-ILT
Agency product number
EMEA/V/C/003869
Active substance
Cell-associated live recombinant turkey herpesvirus (strain HVT/ILT-138), expressing the glycoproteins gD and gI of infectious laryngotracheitis virus
International non-proprietary name (INN) or common name
avian infectious laryngotracheitis and Marek’s disease vaccine (live)
Species
Chicken
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI01AD03
Publication details
Marketing-authorisation holder
Intervet International B.V.
Revision
5
Date of issue of marketing authorisation valid throughout the European Union
03/07/2015
Contact address

Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands

Product information

09/09/2021 Innovax-ILT - EMEA/V/C/003869 - WS2102/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Immunologicals for aves

  • Live viral vaccines

Therapeutic indication

For active immunisation of one-day-old chicks to reduce mortality, clinical signs and lesions due to infection with avian infectious laryngotracheitis (ILT) virus and Marek’s disease (MD) virus.

Assessment history

How useful was this page?

Add your rating